FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083410780> ?p ?o ?g. }

• W3083410780 endingPage "12" @default.
• W3083410780 startingPage "11" @default.
• W3083410780 abstract "CD248 is a transmembrane receptor whose realized ligands are fibronectin and type I/IV collagen. It is broadly communicated on mesenchymal cells during undeveloped life and is required for multiplication and movement of pericytes and fibroblasts. In spite of the fact that CD248 articulation is drastically decreased during grown-up life, it might be upregulated during explicit conditions, for example, danger, aggravation, and fibrosis. It is notable that CD248 is communicated on the outside of cells of mesenchymal source, including tumor-related pericytes and initiated fibroblasts, which are thought to assume a key job in the advancement of tumor neovascular systems and stromal association. The interference of endosialin work, with immune response bar or hereditary knockouts, adversely influences tumor development and angiogenesis in various malignancy types. Besides, in the exploratory model of kidney fibrosis after one-sided ureteral check (UUO), CD248−/− mice show downregulation of myofibroblast expansion, hence diminishing the kidney fibrosis. These biologic impacts, in malignancy and in reparative reaction, might be identified with the capacity of CD248 to adjust many flagging pathways engaged with both disease advancement and tissue fix, including platelet-determined development factor BB (PDGF-BB), changing development factor-β (TGF-β), and Notch receptor protein. Under ordinary conditions, pericytes that communicated elevated levels of CD248 had the option to multiply, reacting to PDGF-BB incitement, and higher articulation of CD248 is required for granting fibroblast affectability with the impacts of TGF-β . Attributable to its multifunctional exercises balancing intrinsic insusceptibility, cell multiplication, and vascular homeostasi, CD248 might be viewed as an expected restorative objective for a few ailments, and presently, the aftereffects of a first-in-human, open-mark, stage I study enlisting patients with extracranial strong tumors who bombed standard chemotherapy and were treated with a biologic treatment focusing on CD248 have been distributed, affirming the treatment’s security and a positive effect on various malignancies. Foundational sclerosis (SSc) is a connective tissue ailment of obscure etiology with multiorgan contribution and heterogeneous clinical signs. The sign of early SSc is endothelial contribution, while later stages are portrayed by an unnecessary gathering of extracellular network (ECM), bringing about expanded fibrosis in skin and inside organs. Over the most recent couple of years, it has been explained that endothelial cells (ECs) and pericytes, after injury, may separate toward myofibroblasts, which are focused on delivering expanded measures of collagen, and this cycle has been proposed as a key pathogenic instrument in SSc. A few polypeptide arbiters are associated with fibrosis during SSc, for example, TGF-β and PDGF-BB. The last is a strong supportive of proliferative sign for mesenchyme-inferred cells, including myofibroblasts, while TGF-β fundamentally advances myofibroblast enactment, α-smooth muscle actin (α-SMA) articulation, and collagen affidavit. Strikingly, CD248 adjusts both these pathways due to CD248 is required for giving fibroblast affectability with the impacts of TGF-β and is significant for ideal transitory reaction of actuated fibroblasts to PDGF-BB. The objective of this work is to explore the outflow of CD248 in skin perivascular stromal cells from patients with SSc and its capacity in interceding pericyte separation toward myofibroblasts. Despite the fact that the job of CD248 in the pathogenesis of SSc has not yet been built up, its possible job in controlling vessel relapse and fibrosis makes this particle a likely remedial objective in a clinical setting, unique in relation to malignant growth, and in which a viable restorative way to deal with forestall fibrosis is as yet a significant neglected need." @default.
• W3083410780 created "2020-09-11" @default.
• W3083410780 creator A5051871418 @default.
• W3083410780 date "2020-01-01" @default.
• W3083410780 modified "2023-09-23" @default.
• W3083410780 title "The CD248 Expression on Myofibroblast Cells May Contribute to Exacerbate the Microvascular Damage During Systemic Sclerosis" @default.
• W3083410780 hasPublicationYear "2020" @default.
• W3083410780 type Work @default.
• W3083410780 sameAs 3083410780 @default.
• W3083410780 citedByCount "0" @default.
• W3083410780 crossrefType "journal-article" @default.
• W3083410780 hasAuthorship W3083410780A5051871418 @default.
• W3083410780 hasConcept C104317684 @default.
• W3083410780 hasConcept C127561419 @default.
• W3083410780 hasConcept C142724271 @default.
• W3083410780 hasConcept C198826908 @default.
• W3083410780 hasConcept C203014093 @default.
• W3083410780 hasConcept C207865475 @default.
• W3083410780 hasConcept C2780394083 @default.
• W3083410780 hasConcept C2780559512 @default.
• W3083410780 hasConcept C502942594 @default.
• W3083410780 hasConcept C54355233 @default.
• W3083410780 hasConcept C71924100 @default.
• W3083410780 hasConcept C86803240 @default.
• W3083410780 hasConcept C95444343 @default.
• W3083410780 hasConceptScore W3083410780C104317684 @default.
• W3083410780 hasConceptScore W3083410780C127561419 @default.
• W3083410780 hasConceptScore W3083410780C142724271 @default.
• W3083410780 hasConceptScore W3083410780C198826908 @default.
• W3083410780 hasConceptScore W3083410780C203014093 @default.
• W3083410780 hasConceptScore W3083410780C207865475 @default.
• W3083410780 hasConceptScore W3083410780C2780394083 @default.
• W3083410780 hasConceptScore W3083410780C2780559512 @default.
• W3083410780 hasConceptScore W3083410780C502942594 @default.
• W3083410780 hasConceptScore W3083410780C54355233 @default.
• W3083410780 hasConceptScore W3083410780C71924100 @default.
• W3083410780 hasConceptScore W3083410780C86803240 @default.
• W3083410780 hasConceptScore W3083410780C95444343 @default.
• W3083410780 hasIssue "5" @default.
• W3083410780 hasLocation W30834107801 @default.
• W3083410780 hasOpenAccess W3083410780 @default.
• W3083410780 hasPrimaryLocation W30834107801 @default.
• W3083410780 hasRelatedWork W119637295 @default.
• W3083410780 hasRelatedWork W2001805545 @default.
• W3083410780 hasRelatedWork W2018079417 @default.
• W3083410780 hasRelatedWork W2020124228 @default.
• W3083410780 hasRelatedWork W2042606264 @default.
• W3083410780 hasRelatedWork W2047839770 @default.
• W3083410780 hasRelatedWork W2075111778 @default.
• W3083410780 hasRelatedWork W2076044490 @default.
• W3083410780 hasRelatedWork W2119624611 @default.
• W3083410780 hasRelatedWork W2135276143 @default.
• W3083410780 hasRelatedWork W2155187432 @default.
• W3083410780 hasRelatedWork W2374239590 @default.
• W3083410780 hasRelatedWork W2411149830 @default.
• W3083410780 hasRelatedWork W2549591147 @default.
• W3083410780 hasRelatedWork W2567880634 @default.
• W3083410780 hasRelatedWork W2593899782 @default.
• W3083410780 hasRelatedWork W2885244105 @default.
• W3083410780 hasRelatedWork W3008865088 @default.
• W3083410780 hasRelatedWork W3116575220 @default.
• W3083410780 hasRelatedWork W3141319167 @default.
• W3083410780 hasVolume "10" @default.
• W3083410780 isParatext "false" @default.
• W3083410780 isRetracted "false" @default.
• W3083410780 magId "3083410780" @default.
• W3083410780 workType "article" @default.